Genentech's Lucentis improves vision in RVO Phase III study
This article was originally published in Scrip
Genentech's VEGF inhibitor Lucentis (ranibizumab) has been shown to improve the vision of patients with retinal vein occlusion (RVO) in a Phase III study.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.